Can Biogen Dethrone Baxter in Hemophilia?
Todd Campbell, The Motley Fool - Motley Fool - Fri Apr 25, 5:30PM CDT
Drugmakers like Biogen are enjoying a new wave of success as they usher next-generation therapies to market that are displacing prior treatments. Gilead has de-throned injectible drugs as the standard of care with a faster and better working...
SmarTrend Watching for Potential Rebound in Shares of Biogen Idec After 3.06% Loss
Comtex SmarTrend(R) - Fri Apr 25, 4:01PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $285.58 to a high of $296.74. Yesterday, the shares fell 3.1%, which took the trading range below the 3-day low of $286.48 on volume of 1.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Watch for Biogen Idec to Potentially Rebound After Falling 3.06% Yesterday
Comtex SmarTrend(R) - Fri Apr 25, 4:00PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $285.58 to a high of $296.74. Yesterday, the shares fell 3.1%, which took the trading range below the 3-day low of $286.48 on volume of 1.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
PharmaPoint: Crohn's Disease - Current and Future Players
M2 - Fri Apr 25, 9:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4n3bcj/pharmapoint) has announced the addition of the "PharmaPoint: Crohn's Disease - Current and Future Players" report to their offering. PharmaPoint: Crohn's Disease - Current and Future Players. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Crohn's Disease Market. The report identifies and analyses the key companies shaping and driving the global Crohn's Disease market. The report provides insight into the competitive Crohn's Disease landscape, including new companies entering the market. Scope - Investigation of current and future market competition for Crohn's Disease - Competitor assessment - Coverage of key market players and company profiles including business description, financial overview and SWOT analysis. - Strategic assessment of Crohn's Disease sector through market impact analysis, future market scenario and company analysis Key Topics Covered: - Tables & Figures - Introduction - Market Outlook - Current and Future Players - Appendix Companies Mentioned - Johnson & Johnson - AbbVie - UCB - Biogen Idec - Takeda - ChemoCentryx For more information visit http://www.researchandmarkets.com/research/4n...harmapoint
Quintiles enters into comprehensive clinical development partnership with Biogen Idec
M2 - Fri Apr 25, 6:01AM CDT
Biopharmaceutical company Quintiles revealed on Thursday the launch of a multi year strategic clinical development agreement with Biogen Idec (NasdaqGS:BIIB).
Why Xilinx Inc., Biogen Idec Inc., and Qualcomm Incorporated Are Today’s 3 Worst Stocks
John Divine, The Motley Fool - Motley Fool - Thu Apr 24, 7:04PM CDT
U.S. manufacturers are starting to hit their strides this spring, according to new data from the Census Bureau. Durable goods orders rose 2.6% in March from February, notably better than the 2% increase expected by Econoday; the strong demand is a...
Why Investors Should Love Biogen's Earnings Miss
Dan Carroll, The Motley Fool - Motley Fool - Thu Apr 24, 5:30PM CDT
Big biotech Biogen Idec has weathered the industry's storm in a rocky 2014. The stock's gained more than 9% despite the biotech sector's fall brought on by nervous investors concerned about the market's rally, and Biogen has plenty of room for...
Spectrum Pharma Candidate Gets Positive Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 4:50PM CDT
Spectrum Pharmaceuticals (SPPI) announced encouraging results from a phase II pivotal study on captisol-enabled melphalan.
Stock Market News for April 24, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 9:06AM CDT
Benchmarks ended lower on Wednesday following disappointing corporate results and economic data
Earnings Roundup: Biogen's Tecfidera Wins More Share
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 24, 8:30AM CDT
Biogen remains a market leader in treating multiple sclerosis, an autoimmune disease that affects more than 1.1 million people in the U.S. and Europe. The company has launched a host of widely successful MS therapies over the past decade,...
Ambit Biosciences Slumps: AMBI Falls 7.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 7:49AM CDT
Ambit Biosciences saw a big move last session, as the company’s shares fell by over 7% on the day
Prothena Corporation plc (PRTA) Worth Watching: Stock Rises 9.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 7:44AM CDT
Prothena Corporation plc (PRTA) was a big mover last session, as the company saw its shares rally nearly 10.00% on the day.
Quintiles and Biogen Idec Announce Comprehensive Clinical Development Partnership
Business Wire - Thu Apr 24, 7:00AM CDT
Quintiles, the world's largest provider of biopharmaceutical development and commercial outsourcing services, and Biogen Idec (NASDAQ: BIIB) have entered into a five-year strategic clinical development agreement. The multi-year collaboration is designed to leverage the expertise and experience from both organizations to optimize Biogen Idec's clinical development processes.
Biogen EPS misses, guides up
at Investor's Business Daily - Wed Apr 23, 5:49PM CDT
The biotech's Q1 EPS jumped 25% to $2.47, but missed views by 9 cents. Revenue rose 50.5% to $2.13 bil, above views for $2 bil. U.S. sales of MS drug Tecfidera were $460 mil vs. views of $413 mil. Nearly all individual product sales beat consensus....
Biogen Q1, Guidance Strong
at Investor's Business Daily - Wed Apr 23, 5:46PM CDT
Big-cap biotech Biogen Idec reported solid Q1 revenue early Wednesday and guided 2014 above Wall Street's expectations, but the stock rose just a fraction as biotechs had a bad day and Biogen revealed it's being probed by authorities. Biogen (BIIB)...
Why Biogen (BIIB) Stock Is Down Today
at The Street - Wed Apr 23, 12:55PM CDT
Biogen (BIIB) shares fall as Biotech ETF as takes a hit in trading today
Biogen's Q1 Earnings Soar Y/Y on Tecfidera Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 12:40PM CDT
Although Biogen (BIIB) missed earnings estimates, revenues surpassed expectations easily. The company also raised its guidance.
Interesting BIIB Put And Call Options For June 21st
at The Street - Wed Apr 23, 10:05AM CDT
Investors in Biogen Idec Inc saw new options begin trading this week, for the June 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB options chain for the new June 21st contracts and identified one put...
Biogen Q1 Sales Beat Street, Guidance Strong
at Investor's Business Daily - Wed Apr 23, 9:11AM CDT
Big-cap biotech Biogen Idec (BIIB) reported solid Q1 revenue early Wednesday and guided 2014 above Wall Street's expectations, but the stock was down more than 1% in early trading in the stock market today. Biogen said revenue rose 50.5% over the...
Amgen's Q1 Earnings Decline Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 8:40AM CDT
Amgen's first quarter results were disappointing with most of the products recording a sequential decline in sales.